The effects of treatment with budesonide (200 pg twice daily) and terbutaline (500 pg four times daily) has been compared with the effects of placebo and terbutaline in 27 children with mild asthma, aged 7-14 years, in a double blind, randomised placebo controlled study over eight weeks. Bronchial responsiveness (PC20 histamine), lung function, the amplitude of diurnal variation in peak expiratory flow (PEF), and symptom scores were measured. Baseline FEV, was over 70% predicted and PC20 histamine less than 8 mg/ml. Twelve children were treated with budesonide and terbutaline and 15 with placebo and terbutaline. After four and eight weeks of treatment the change in PC20 was significantly greater after budesonide and terbutaline than after terbutaline alone by 2-1 (95% CI 0-5-3 8) and 1-3 (95% CI 0-1-2-5) doubling doses respectively. Mean FEV, did not change in either group. The change in afternoon and nocturnal PEF was significantly greater after budesonide and terbutaline than after terbutaline alone. The amplitude of diurnal variation in PEF did not change significantly in either group. Peak flow reversibility decreased in the budesonide group. There were no differences between treatments for cough and dyspnoea, but wheeze improved in the budesonide group. The children with mild asthma treated with budesonide and terbutaline showed improvement in bronchial responsiveness, afternoon and nocturnal PEF, and symptoms of wheeze and a fall in peak flow reversibility by comparison with those who received terbutaline alone.
Bronchial hyperresponsiveness, a common feature of asthma in adults and children,' can be assessed by inhalation provocation tests with histamine or methacholine. Viral infection, ozone exposure, and a late asthmatic reaction after allergen challenge may induce an increase in bronchial responsiveness, 24 suggesting that inflammatory processes are important in its development. Maintenance treatment with anti-inflammatory drugs, such as budesonide and beclomethasone, reduces bronchial responsiveness in children and adults with asthma, and this has been ascribed to a reduction in airway inflammation. 56 Bronchial smooth muscle contraction also contributes to bronchoconstriction and is often treated by beta2 agonists. An increased amplitude in the diurnal variation in measures of airflow is seen in asthma and is thought to reflect the severity of the disease. 7 We have investigated whether the addition of budesonide to maintenance treatment with terbutaline can improve respiratory symptoms, pulmonary function, bronchodilator response, bronchial responsiveness, and the amplitude of diurnal variation in peak flow (PEF) in children with mild asthma. The study had a parallel group double blind design.
Methods

PATIENTS
Thirty two asthmatic children aged 7-14 (mean 10 3) years were included. All had a history of episodic shortness of breath or wheeze or both, bronchial hyperresponsiveness with a provocative concentration of histamine causing a 20% fall in FEV, (PC20) of 8 mg/ml or less, and a positive skin test response or specific IgE against one or more common allergens.
All children had mild symptoms that were controlled by an inhaled beta2 agonist or sodium cromoglycate or both. None of the children had children received terbutaline (500 ug four times daily) and placebo (twice daily). After the run in period the inclusion criteria were checked again and for the next eight weeks the children received either budesonide (200 jg twice daily) and terbutaline (500 Mg four times daily) or placebo and terbutaline (500 jg four times daily). Budesonide and placebo were administered with a 750 ml spacer device (Nebuhaler) and terbutaline with a smaller spacer device. When needed, up to four additional terbutaline puffs (250 jig) were allowed a day.
The children recorded daily PEF (mini Wright, best of three attempts) at 8 am and 4 pm, before and 10 minutes after inhaling 500 jig terbutaline, during the run in period and during weeks 3, 4, 7, and 8 of the double blind treatment phase. The children were woken by their parents at 4 am twice in the week before each visit to the outpatient department for measurement of nocturnal PEF. Cough, wheeze, and dyspnoea were recorded daily on a 0-3 scale (0 = no and 3 = severe symptoms).
FEV, and PC20 histamine were measured before and after the run in period and after four and eight weeks of treatment. Patients' compliance was assessed by weighing the metered dose inhalers before and after use.
LUNG FUNCTION AND INHALATION PROVOCATION TESTS
Measurements were carried out 12-16 hours after the last drug inhalation and were always performed in each subject at the same time of the day. Forced expiratory volume in one second (FEVI) and forced vital capacity (FVC) were determined with a water sealed spirometer (Lode, Groningen, The Netherlands). The best of three reproducible efforts was used for data analysis.
The histamine provocation was performed according to the Cockcroft method.9 The solutions were nebulised with a gauged DeVilbiss 646 nebuliser (output 0 13 ml/min) attached to an inspiratory-expiratory valve box. After inhalation ofisotonic saline, phosphate buffered histamine was inhaled in doubling concentrations from 0-03 to 16 mg/ml. Each dose was inhaled for two minutes at five minute intervals with tidal breathing while the nose was clipped, until there was a fall in FEV, of 20% from baseline FEV, or until the maximum concentration of histamine had been inhaled. The histamine values at visits 3 and 4 were compared with the data just before the double blind treatment period (visit 2). Mean PEF recordings and symptom scores measured in weeks 3 + 4 and weeks 7 + 8 of treatment were compared with the values in the run in period. We considered a p value of 0 05 to be statistically significant. Power analysis showed a probability of 80% of obtaining a significant result if the difference between PC20 histamine in the two groups was 1 5 doubling concentrations, on the assumption of a standard deviation of 1 5 doubling dose steps.
Results
Thirty two children were included in the study. Five children (three in the budesonide group and two in the terbutaline only group) were withdrawn before entering the treatment period for the following reasons: FEV, fell below 70% predicted (one child), PC20 histamine rose above 8 mg/ml (one), non-compliance (one), and asthma symptoms increased (two). The mean PC20 and FEV, % predicted of thosewithdrawn did not differ significantly from values in patients who completed the study.
Of the 27 children completing the study, 12 children were treated with budesonide and day in the run in period to 6-8 in the first and 7 5 in the second month of treatment (NS). In the budesonide group terbutaline use decreased significantly from 6 7 puffs a day in the run in period to 5 7 in the first and 5 7 in the second month (p < 005). In the second month of treatment terbutaline use was lower in the budesonide group than in the terbutaline only group (p < 0 05).
Discussion
In the present study we investigated the effect of adding budesonide to regular treatment with terbutaline. We observed a decrease in bronchial responsiveness with budesonide and terbutaline treatment by comparison with terbutaline alone. There was a slight increase in bronchial responsiveness to histamine after four weeks' treatment with terbutaline alone but not after eight weeks' treatment. A few studies have focused on the relation between the use of beta2 agonists and bronchial responsiveness. Peel and Gibson found no significant difference in PC20 histamine measured before and four weeks after treatment with salbutamol. " Kraan et al6 showed a slight but significant increase in bronchial responsiveness to histamine after two weeks' inxhaled terbutaline, which was not significant at four weeks. These findings were confirmed by Kerrebijn The amplitude of the diurnal variation in PEF is higher in asthmatic patients than in normal subjects and has been shown to fall during treatment with inhaled corticosteroids6 and increase after their withdrawal.303' The amplitude of diurnal variation in PEF was low in both groups in our study and there were no significant differences in the changes between the two groups. This again may be because the children had little or no bronchial obstruction, or possibly it is due in part to the terbutaline given in the run in period.32 Although some investigators include postbronchodilator values to express amplitude of diurnal variation in PEF,33 this seems to us to reflect diurnal variation in PEF less accurately, because it also includes the peak flow response to a bronchodilator. Studies that include postbronchodilator PEF values in the calculation of PEF variation are difficult to compare as they differ with regard to the time of measuring postbronchodilator PEF and the type and dose of bronchodilating drug. When postbronchodilating PEF values were included in our analysis, we found that peak flow reversibility decreased significantly in the budesonide group by comparison with the terbutaline only group. We have no plausible explanation for the difference in the effects of budesonide on PEF variation and PEF reversibility.
We conclude that in children with mild asthma and increased bronchial responsiveness treatment with budesonide in addition to regular treatment with inhaled terbutaline over eight weeks leads to an improvement in bronchial responsiveness, an increase in afternoon and nocturnal PEF values, and a decrease in peak flow reversibility and symptoms of wheeze.
variation in peak flow. bronchial hyperresponsiveness and diurnal on alone in children with mild asthma: effects
